阿巴西普治疗类风湿关节炎患者的长期安全性。

Long-term safety of abatacept in patients with rheumatoid arthritis.

机构信息

Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.

出版信息

Autoimmun Rev. 2013 Oct;12(12):1115-7. doi: 10.1016/j.autrev.2013.06.011. Epub 2013 Jun 22.

DOI:10.1016/j.autrev.2013.06.011

Abstract

Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.

摘要

阿巴西普是一种选择性 T 细胞共刺激调节剂，最初在意大利被药品管理局批准，并被意大利国家卫生服务系统报销，用于治疗“对其他疾病改善抗风湿药物（DMARDs），包括至少一种 TNF 抑制剂，反应不足的”活动期类风湿关节炎，现在也被批准为一线生物制剂。本综述的目的是总结临床试验和观察性研究中收集的安全性数据。